Search the website

Search results

1236 results

Sort by

List item

Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Superseded (PDF/803.95 KB)

Adopted
First published: 09/10/2017
Last updated: 22/11/2019
Legal effective date: 09/10/2017
EMA/CHMP/302620/2017 Corr.1
Bulgarian
(PDF/839.88 KB)

Croatian
(PDF/817.47 KB)

Czech
(PDF/820.69 KB)

Danish
(PDF/775.32 KB)

Dutch
(PDF/774.1 KB)

Estonian
(PDF/748.01 KB)

Finnish
(PDF/768.01 KB)

French
(PDF/796.79 KB)

German
(PDF/777.2 KB)

Greek
(PDF/851.84 KB)

Hungarian
(PDF/830.38 KB)

Icelandic
(PDF/770.42 KB)

Italian
(PDF/767.61 KB)

Latvian
(PDF/825.2 KB)

Lithuanian
(PDF/826.31 KB)

Maltese
(PDF/804.36 KB)

Norwegian
(PDF/769.45 KB)

Polish
(PDF/817.25 KB)

Portuguese
(PDF/765.58 KB)

Romanian
(PDF/821.81 KB)

Slovak
(PDF/818.86 KB)

Slovenian
(PDF/805.68 KB)

Spanish
(PDF/703.08 KB)

Swedish
(PDF/745.16 KB)
List item

ICH guideline Q3C (R6) on impurities - support document 3: toxicological data for class 3 solvents - Step 5 (PDF/629.14 KB)

First published: 26/10/2018
Last updated: 15/10/2019
EMA/CHMP/ICH/735038/2018
List item

ICH guideline Q3C (R6) on impurities - support document 2: toxicological data for class 2 solvents - Step 5 (PDF/1006.19 KB)

First published: 26/10/2018
Last updated: 15/10/2019
EMA/CHMP/ICH/735036/2018
List item

ICH guideline Q3C (R6) on impurities - support document 1: toxicological data for class 1 solvents - Step 5 (PDF/644.27 KB)

First published: 26/10/2018
Last updated: 15/10/2019
EMA/CHMP/ICH/735035/2018
List item

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline Q3C (R6) on impurities: guideline for residual solvents - Step 5 (PDF/498.12 KB)

Adopted
First published: 26/10/2018
Last updated: 08/10/2019
Legal effective date: 14/06/2017
EMA/CHMP/ICH/82260/2006
List item

Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance (PDF/174.37 KB)

Adopted
First published: 03/01/2017
Last updated: 09/08/2019
Legal effective date: 01/07/2017
EMA/CHMP/154812/2016 Rev.1 Corr.
List item

Draft guideline on clinical investigation of medicinal products for the treatment of gout - First version (PDF/331.79 KB)

Draft: consultation closed
First published: 08/02/2019
Last updated: 07/08/2019
Consultations dates: from 08/02/2019 to 31/08/2019
EMA/CHMP/774470/2018
List item

Draft qualification opinion of Multiple sclerosis clinical outcome assessment (MSCOA) (PDF/1.08 MB)

Draft: consultation closed
First published: 19/06/2019
Last updated: 02/07/2019
Consultations dates: from 18/06/2019 to 20/09/2019
EMA/CHMP/SAWP/336445/2019 Corr.1
List item

Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1 (PDF/455.51 KB)

Adopted
First published: 07/11/2018
Last updated: 29/04/2019
Legal effective date: 30/04/2019
CPMP/EWP/239/95 Rev. 1 Corr.
List item

Draft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 2 (PDF/575.99 KB)

Draft: consultation closed
First published: 30/11/2018
Last updated: 19/12/2018
Consultations dates: from 03/12/2018 to 30/06/2019
EMA/CHMP/BPWP/144552/2009 rev. 2 Corr.1
List item

Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) (PDF/422.33 KB)

Draft: consultation closed
First published: 19/11/2018
Last updated: 12/12/2018
Consultations dates: from 19/11/2018 to 31/08/2019
EMA/CHMP/299976/2018
List item

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use (PDF/132.89 KB)

Adopted
First published: 09/10/2017
Last updated: 19/11/2018
EMA/CHMP/606830/2014 Corr.1
List item

Information for the package leaflet regarding aspartame and phenylalanine used as excipients in medicinal products for human use (PDF/330.41 KB)

Adopted
First published: 09/10/2017
Last updated: 19/11/2018
EMA/CHMP/134648/2015 Corr.1
List item

Questions and answers on wheat starch (containing gluten) used as an excipient in medicinal products for human use (PDF/131.08 KB)

Adopted
First published: 09/10/2017
Last updated: 19/11/2018
EMA/CHMP/704219/2013 Corr.1
List item

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 1 (PDF/210.49 KB)

Adopted
First published: 26/10/2017
Last updated: 07/11/2018
Legal effective date: 26/04/2018
EMA/CHMP/BWP/534898/2008 Rev. 1 corrigendum
List item

Draft concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1 (PDF/91.07 KB)

Draft: consultation closed
First published: 17/09/2018
Last updated: 17/09/2018
Consultations dates: from 17/09/2018 to 16/12/2018
EMA/PDCO/362462/2016
List item

Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3 (PDF/727.6 KB)

Draft: consultation closed
First published: 17/08/2018
Last updated: 17/08/2018
Consultations dates: from 17/08/2018 to 17/02/2019
CHMP/EWP/566/98
List item

Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) - Revision 1 (PDF/150.49 KB)

Draft: consultation closed
First published: 15/08/2018
Last updated: 15/08/2018
Consultations dates: from 15/08/2018 to 15/02/2019
EMEA/CHMP/BMWP/31329/2005
List item

Guideline on core summary for product characteristics for human albumin solution - Revision 3 (PDF/122.8 KB)

Adopted
First published: 13/08/2018
Last updated: 13/08/2018
Legal effective date: 01/02/2019
EMA/CHMP/BPWP/494462/2011
List item

Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 2 (PDF/492.58 KB)

Adopted
First published: 13/08/2018
Last updated: 13/08/2018
Legal effective date: 01/02/2019
EMA/CHMP/BPWP/144533/2009
List item

Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products - Revision 3 (PDF/191.38 KB)

Adopted
First published: 13/08/2018
Last updated: 13/08/2018
Legal effective date: 01/02/2019
EMA/CHMP/BPWP/1619/1999
List item

Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies (PDF/126.46 KB)

Draft: consultation closed
First published: 06/08/2018
Last updated: 06/08/2018
Consultations dates: from 06/08/2018 to 31/10/2018
EMA/CHMP/459559/2018
List item

ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version (PDF/351.95 KB)

Draft: consultation closed
First published: 06/08/2018
Last updated: 06/08/2018
Consultations dates: from 06/08/2018 to 06/02/2019
EMA/CHMP/ICH/493213/2018
List item

Agomelatine tablet 25 mg product-specific bioequivalence guidance (PDF/83.4 KB)

Adopted
First published: 03/08/2018
Last updated: 03/08/2018
EMA/CHMP/800802/2017
List item

Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance (PDF/91.2 KB)

Adopted
First published: 03/08/2018
Last updated: 03/08/2018
EMA/CHMP/800785/2017

1236 results

Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668) - Superseded (PDF/803.95 KB)

ICH guideline Q3C (R6) on impurities - support document 3: toxicological data for class 3 solvents - Step 5 (PDF/629.14 KB)

ICH guideline Q3C (R6) on impurities - support document 2: toxicological data for class 2 solvents - Step 5 (PDF/1006.19 KB)

ICH guideline Q3C (R6) on impurities - support document 1: toxicological data for class 1 solvents - Step 5 (PDF/644.27 KB)

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline Q3C (R6) on impurities: guideline for residual solvents - Step 5 (PDF/498.12 KB)

Fingolimod capsules 0.25 and 0.5 mg product-specific bioequivalence guidance (PDF/174.37 KB)

Draft guideline on clinical investigation of medicinal products for the treatment of gout - First version (PDF/331.79 KB)

Draft qualification opinion of Multiple sclerosis clinical outcome assessment (MSCOA) (PDF/1.08 MB)

Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1 (PDF/455.51 KB)

Draft guideline on clinical investigation of recombinant and human plasma-derived factor IX products - Revision 2 (PDF/575.99 KB)

Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) (PDF/422.33 KB)

Questions and answers on sodium laurilsulfate used as an excipient in medicinal products for human use (PDF/132.89 KB)

Information for the package leaflet regarding aspartame and phenylalanine used as excipients in medicinal products for human use (PDF/330.41 KB)

Questions and answers on wheat starch (containing gluten) used as an excipient in medicinal products for human use (PDF/131.08 KB)

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials - Revision 1 (PDF/210.49 KB)

Draft concept paper on the need for revision of the guideline on the investigation of medicinal products in the term and preterm neonate - Revision 1 (PDF/91.07 KB)

Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3 (PDF/727.6 KB)

Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) - Revision 1 (PDF/150.49 KB)

Guideline on core summary for product characteristics for human albumin solution - Revision 3 (PDF/122.8 KB)

Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products - Revision 2 (PDF/492.58 KB)

Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products - Revision 3 (PDF/191.38 KB)

Draft guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies (PDF/126.46 KB)

ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version (PDF/351.95 KB)

Agomelatine tablet 25 mg product-specific bioequivalence guidance (PDF/83.4 KB)

Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance (PDF/91.2 KB)